Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
Cytokinetics Inc. President and CEO Robert I. Blum reported an open-market sale of 7,500 shares of common stock at $77.21 per share. Following this sale, he holds 392,830 shares directly. Separate trust holdings reported as of the same date each hold 2,083 shares indirectly.
CYTOKINETICS INC director Muna Bhanji received new equity compensation. On 2026-05-27, Bhanji was granted 2,851 shares of common stock at no cost, increasing direct holdings to 26,361 shares.
Bhanji was also awarded a non-qualified stock option for 4,301 shares of common stock at an exercise price of $77.15 per share. The option becomes exercisable on 2026-06-28 and expires on 2036-05-26.
CYTOKINETICS INC director James M. Daly received new equity awards in the form of shares and stock options. He was granted 2,851 shares of Common Stock at no cost, increasing his direct holdings to 3,239 shares. He also received a non-qualified stock option covering 4,301 shares of Common Stock at an exercise price of $77.15 per share. This option becomes exercisable starting on June 27, 2026 and expires on May 26, 2036, reflecting routine equity-based director compensation rather than an open-market purchase.
Harrington Robert Arthur reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics director Robert Arthur Harrington received equity compensation in the form of common stock and stock options. He was granted 2,851 shares of common stock and now holds 21,781 shares directly.
He was also granted 4,301 non-qualified stock options exercisable at $77.15 per share, expiring on May 26, 2036, linked to 4,301 shares of common stock.
CYTOKINETICS INC director John T. Henderson reported new equity awards. He received a grant of 2,851 shares of common stock at no cost, bringing his direct holdings to 78,088 shares. He was also granted a non-qualified stock option for 4,301 shares at an exercise price of $77.1500 per share, exercisable starting on June 27, 2026 and expiring on May 26, 2036. In addition, 83 shares are reported as indirectly owned through his spouse. These are compensation-related awards, not open-market purchases or sales.
CYTOKINETICS INC director Edward M. Kaye, MD received new equity compensation. He was granted 2,851 shares of Common Stock and now directly holds 13,216 shares. He also received a non-qualified stock option for 4,301 shares at an exercise price of $77.15 per share, exercisable beginning on June 27, 2026 and expiring on May 26, 2036.
Cytokinetics director B. Lynne Parshall received new equity awards. On 2026-05-27, she was granted 2,851 shares of Cytokinetics common stock at no cost, increasing her direct holdings to 20,784 shares.
She was also granted a non-qualified stock option for 4,301 shares of common stock at an exercise price of $77.15 per share, expiring on 2036-05-26. These awards are compensation-related grants rather than open-market purchases or sales.
CYTOKINETICS INC director Robert E. Landry reported equity grants. He received 2,851 shares of Common Stock at no cost, increasing his direct holdings to 10,184 shares. He was also granted a non-qualified stock option for 4,301 shares at an exercise price of $77.15, exercisable starting on June 27, 2026 and expiring on May 26, 2036.
Cytokinetics Inc. director Wendell Wierenga reported equity compensation awards. On May 27, 2026, he received 2,851 shares of Common Stock as a grant at no cash cost, increasing his direct holdings to 35,488 shares.
He was also granted a Non-Qualified Stock Option for 4,301 shares of Common Stock at an exercise price of $77.15 per share. This option is scheduled to become exercisable starting June 27, 2026 and expires on May 26, 2036, adding to his long-term incentive position with the company.
Cytokinetics director Nancy Wysenski received new equity awards in the form of common shares and stock options. She was granted 2,851 shares of Common Stock at no purchase price, increasing her directly held stake to 33,917 shares. She also received a Non-Qualified Stock Option covering 4,301 shares of Common Stock with an exercise price of $77.1500 per share, exercisable into the same number of underlying shares and expiring on May 26, 2036. These awards are classified as grants or awards rather than open-market purchases or sales.